Trial Profile
Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Obinutuzumab (Primary) ; Prednisone (Primary) ; Venetoclax (Primary)
- Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 12 Dec 2023 Results (n=50) assessing safety and efficacy of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Aug 2023 Planned number of patients changed from 130 to 145.
- 13 Dec 2022 Results (n=30)of analysis assessing Safety, Efficacy, and Minimal Residual Disease presented at the 64th American Society of Hematology Annual Meeting and Exposition